Viking Therapeutics Stock Surges on Acquisition Speculation
Published on 10/11/2025 at 19:18 | Redaktion boerse-global.de
Shares of Viking Therapeutics experienced a substantial rally on Friday, climbing 8.1% as investor enthusiasm built around the company’s potential as a takeover target. The broader biotechnology sector is currently gripped by merger fever, with Viking emerging as a central figure in speculation concerning potential billion-dollar transactions.
The catalyst for this upward movement occurred on Thursday when Novo Nordisk revealed its plan to acquire Akero Therapeutics, a direct competitor in the MASH liver disease treatment segment. This announcement not only propelled Akero’s stock significantly higher but also ignited a widespread rally across biotechnology companies with similar developmental pipelines.
Viking Therapeutics benefited immediately from this sector-wide momentum, posting gains of approximately 5% on Thursday before extending those advances into Friday’s... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
